Scientists in the field of drug discovery, particularly biologics, use DLS to make critical decisions about drug candidate stability. This creates a need for instruments that exhibit strong sizing accuracy and precision. These properties can be evaluated using standards and references from the National Institute of Standards and Technology (NIST). Here, the NIST monoclonal antibody (NISTmAb) reference material (RM) RM8671, Lysozyme, and a set of monodisperse particle size standards were used to test the sizing accuracy and intra-assay precision of Prometheus Panta’s DLS optical module.
Looking for the optimal formulation for your biologics candidates?
NanoTemper tools can help
See more related content
1:41Prometheus Panta: The new gold standard for biologics characterization
Choosing the right stability characterization tool for your biologics research is a big commitment. You’re going to be screening and optimizing lots of candidates, and you’ll need data on thermal stab
Use of self-interaction parameters derived from light scattering experiments for better developability assessment of biologic therapeutics
34:16Join this webinar to learn about the physical phenomenon that drives Dynamic Light Scattering (DLS), and see a few examples of how DLS gives you deeper insights.
What is Dynamic Light Scattering (and 4 reasons it’s useful for protein research)
Any researcher looking to better understand their protein’s behavior can benefit from the information provided by Dynamic Light Scattering (DLS). Here’s an overview of DLS and how it’s useful for...
25:16Dynamic Light Scattering (DLS) is a technique that allows researchers to accurately size their biologic molecules and determine the distribution of particle sizes in a solution. In order to turn scatt
18:48Join Thomas Schubert, CEO of 2bind, as he walks through experiments done on the Prometheus Panta to determine the optimal buffer for a vaccine candidate.
30:05The new gold standard in biologic characterization – Develop your biologics faster and better with Prometheus
Development of therapeutic antibodies is a long and costly process. One key indicator of whether biologic candidates will be successful is stability. Prometheus enables rapid and precise characterizat
28:21AbbVie preformulation is an early discovery biologics group working to optimise antibodies prior to downstream assays and clinical delivery. Join Brittney Mills, PhD, as she explains how AbbVie uses
Peptide-MHC I complex stability measured by nanoscale differential scanning fluorimetry reveals molecular mechanism of thermal denaturation
23:44This therapeutic antibody drug development webinar discusses the idea of limiting the substantial investment of time, money, or resources.